Skip to main content
SpringerLink
Log in

Pulmonale Toxizitäten von Krebstherapien - Teil 3

Zytostatische oder zielgerichtete antineoplastische Medikamente

  • Supportivtherapie
  • Published:
Im Fokus Onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

© Klinikum Nürnberg

Literatur

  1. Schreiber J. Medikamenteninduzierte parenchymatöse Lungenerkrankungen [Drug-induced disorders of the lung parenchyma]. Pneumologe (Berl). 2009;6(5):316-27

  2. Eaden JA et al. How consistently do physicians diagnose and manage drug-induced interstitial lung disease? Two surveys of European ILD specialist physicians. ERJ Open Res. 2020;6(1):00286-2019

  3. Skeoch S et al. Drug-Induced Interstitial Lung Disease: A Systematic Review. J Clin Med. 2018;7(10):356

  4. Bonniaud P et al. Drug-induced interstitial lung diseases.Rev Prat. 2014;64(7):951

  5. Bittmann I. Medikamentös induzierte interstitielle Lungenerkrankungen. Pathologe. 2021;42(1):11-6

  6. Reinert T et al. Bleomycin-Induced Lung Injury. J Cancer Res. 2013;2013:480608

  7. O'Sullivan JM et al. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol. 2003;14(1):91

  8. Iacovelli R et al. Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials. Acta Oncol. 2012;51(7):873-9

  9. Liu V et al. Pulmonary toxicity associated with erlotinib. Chest. 2007;132(3):1042-4

  10. Hong D et al. Pulmonary Toxicities of Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials. Medicine. 2016;95(9):e3008. Erratum in: Medicine (Baltimore). 2016;95(30):e156a

  11. Le Guen Y et al. Toxicité pulmonaire induite par l'osimertinib. Rev Mal Respir. 2021; https://doi.org/10.1016/j.rmr.2021.12.002

  12. Conway R et al. Methotrexate and lung disease in rheumatoid arthritis: A meta-analysis of randomized controlled trials. Arthritis Rheumatol. 2014;66(4):803-12

  13. Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis. 2009;68:1100-4

  14. Dimopoulou I et al. A prospective study on lung toxicity in patients treated with gemcitabine and carboplatin: clinical, radiological and functional assessment. Ann Oncol. 2004;15(8):1250-5

  15. Buzdar AU et al. Pulmonary toxicity of mitomycin. Cancer. 1980;45(2):236-44

  16. Belknap SMet al. Clinical features and correlates of gemcitabine-associated lung injury: findings from the RADAR project. Cancer. 2006;106(9):2051-7

  17. Bielopolski D et al. Paclitaxel-induced pneumonitis in patients with breast cancer: case series and review of the literature. J Chemother. 2017;29(2):113

  18. Xiao B et al. Risk of bleeding associated with antiangiogenic monoclonal antibodies bevacizumab and ramucirumab: a meta-analysis of 85 randomized controlled trials. Onco Targets Ther. 2018;11:5059-74

  19. Camus P et al. Pneumotox - An updated time-saving web resource. Eur Resp J. 2013;42(Suppl_42): 5043

  20. Rudmann DG. On-target and off-target-based toxicologic effects. Toxicol Pathol. 2013;41(2):310-4

  21. Riise R et al. Bleomycin hydrolase regulates the release of chemokines important for inflammation and wound healing by keratinocytes. Sci Rep. 2019;9(1):20407

  22. Jóna Á et al. Effect of Bleomycin Hydrolase Gene Polymorphism on Late Pulmonary Complications of Treatment for Hodgkin Lymphoma. PLoS One. 2016;11(6):e0157651

  23. Wijnen PAHM et al. Role of Cytochrome P450 Polymorphisms in the Development of Pulmonary Drug Toxicity. Drug Saf. 2008;31(12):1125-34

  24. Mohammed T et al. Successful Rechallenge with Osimertinib after Very Acute Onset of Drug-Induced Pneumonitis. Case Rep Oncol. 2021;14(2):733-8

  25. Bickert C et al. Osimertinib rechallenge under steroid protection following osimertinib-induced pneumonitis: three case studies. Ther Adv Med Oncol. 2021;13:17588359211018028

  26. Taronna G et al. Transient asymptomatic pulmonary opacities and interstitial lung disease in EGFR-mutated non-small cell lung cancer treated with osimertinib. Tumori. 2021;3008916211047888

  27. Li L et al. Anticancer therapy and lung injury: molecular mechanisms. Expert Rev Anticancer Ther. 2018;18(10):1041-57

  28. CTEP 2019. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm#ctc_50

  29. Mokra D et al. Corticosteroids in Acute Lung Injury: The Dilemma Continues. Int J Mol Sci. 2019;20(19):4765

  30. Fragoulis GE et al. Methotrexate-Associated Pneumonitis and Rheumatoid Arthritis-Interstitial Lung Disease: Current Concepts for the Diagnosis and Treatment. Front Med (Lausanne). 2019;6:238

  31. D'Elia T. Methotrexate-induced pneumonitis: heterogeneity of bronchoalveolar lavage and differences between cancer and rheumatoid arthritis. Inflamm Allergy Drug Targets. 2014;13(1):25-33

  32. Watson RA et al. Development of a best-practice clinical guideline for the use of bleomycin in the treatment of germ cell tumours in the UK. Br J Cancer. 2018;119(9):1044-51

  33. Bui A et al. Pulmonary function testing for the early detection of drug-induced lung disease: a systematic review in adults treated with drugs associated with pulmonary toxicity. Intern Med J. 2020;50(11):1311-25

  34. Kreuter M et al. Diagnostik und Therapie der Lungenfibrosen. Dtsch Arztebl Int. 2021;118(9):152-62

  35. Fernandez AB et al. Statins and interstitial lung disease: a systematic review of the literature and of food and drug administration adverse event reports. Chest. 2008;134(4):824-30

  36. Matsumoto K et al. Analysis of drug-induced interstitial lung disease using the Japanese Adverse Drug Event Report database. SAGE Open Med. 2020;8:2050312120918264

Download references

Author information

Authors and Affiliations

  1. Univ. Klinik f. Inn. Medizin 5, Paracelsus Med. Privatuniversität, Prof.-Ernst-Nathan-Str. 1, 90419, Nürnberg, Deutschland

    Markus Horneber

  2. Institut für Radiologie und Nuklearmedizin, Klinikum Nürnberg, Prof.-Ernst-Nathan-Str. 1, 90419, Nürnberg, Deutschland

    Marco Galster

  3. Universitätsklinik der Paracelsus Medizinischen Privatuniversität | Klinik für Innere Medizin 3, Klinikum Nürnberg, Prof.-Ernst-Nathan-Str. 1, 90419, Nürnberg, Deutschland

    Joachim H. Ficker

Authors
  1. Markus Horneber
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marco Galster
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joachim H. Ficker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Markus Horneber.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Horneber, M., Galster, M. & Ficker, J. Zytostatische oder zielgerichtete antineoplastische Medikamente. Im Fokus Onkologie 25, 28–33 (2022). https://doi.org/10.1007/s15015-022-3784-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15015-022-3784-4

Search

Navigation